Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06137807 · ClinicalTrials.gov registry record · NA
TRIcvalve biCAVal Valve System for Severe Tricuspid Regurgitation (TRICAV-I)
A NA study of Tricuspid Regurgitation and Tricuspid Valve Disease, sponsored by P+F Products + Features USA.
- Recruiting
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 20
- Study locations
NCT06137807: Recruiting NA study of Tricuspid Regurgitation and Tricuspid Valve Disease, sponsored by P+F Products + Features USA.
NCT06137807 is a NA study of Tricuspid Regurgitation and Tricuspid Valve Disease that is actively recruiting participants, run by P+F Products + Features USA. The registered enrollment target is 50 participants, below the 533-participant average among 17 other Tricuspid Regurgitation trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06137807, a NA study of Tricuspid Regurgitation and Tricuspid Valve Disease, is actively recruiting participants, sponsored by P+F Products + Features USA.
- RECRUITING
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 20
- Study locations
Study Summary
The TricValve® Transcatheter Bicaval Valve System is a bicaval transcatheter tricuspid valve replacement system, which includes the TricValve® Transcatheter Bicaval Valve for superior vena cava (SVC) and the TricValve® Transcatheter Bicaval Valve for inferior vena cava (IVC). The TricValve® Transcatheter Bicaval Valves are pre-mounted into the TricValve® Delivery System which is used for percutaneous access and delivery of the TricValve® Transcatheter Bicaval Valve in the vena cava. The system is a single use, sterile device compatible with all the valve sizes. The prostheses are implanted percutaneously into the inferior and superior vena cava without disturbing the native tricuspid valve. The device is made of bovine pericardium leaflets sutured on a nitinol self-expanding stent system.
Primary Outcome
Number of days until death
Conditions Studied
Interventions
- DEVICE TricValve® Transcatheter Bicaval Valve System
Study Locations (20)
Florida
- Delray Medical Center - Delray Beach
- Largo Medical Center - Largo
- Tampa General Hospital - Tampa
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
- Lahey Hospital & Medical Center - Burlington
Arizona
- St. Joseph's Hospital and Medical Center - Phoenix
- Tucson Medical Center - Tucson
California
- Scripps Memorial Hospital La Jolla - San Diego
- UCSF - San Francisco
Illinois
- Endeavor Health, Glenbrook Hospital - Glenview
- Chicago Advocate Christ - Palos Park
Missouri
- Saint Luke's Mid America Heart Institute - Kansas City
- Washington University St Louis - St Louis
New York
- North Shore University Hospital - Manhasset
- Montefiore Medical Center - The Bronx
Indiana
- Ascension Medical Group St. Vincent The Heart Center of Indiana - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2024-07-23 |
| Est. Completion | 2029-09 |
| Phase | NA |
What NCT06137807 shows while recruiting
NCT06137807 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 533-participant average among 17 other Tricuspid Regurgitation trials with a reported enrollment target (91% lower).
The record links to 2 conditions, with Tricuspid Regurgitation appearing as the primary indexed condition, and to 1 intervention - of which TricValve® Transcatheter Bicaval Valve System is the first listed.
NCT06137807 names 20 study sites across 11 states, led by Florida, Massachusetts, Arizona.
Frequently Asked Questions
What is clinical trial NCT06137807 about?
NCT06137807 is a clinical study titled "TRIcvalve biCAVal Valve System for Severe Tricuspid Regurgitation (TRICAV-I)". The TricValve® Transcatheter Bicaval Valve System is a bicaval transcatheter tricuspid valve replacement system, which includes the TricValve® Transcatheter Bicaval Valve for superior vena cava (SVC) and the TricValve® Transcatheter Bicaval Valve for inferior vena cava (IVC). The TricValve® Transcat...
What is the current status of trial NCT06137807?
This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2024-07-23. Estimated completion is 2029-09.
What conditions does trial NCT06137807 study?
This clinical trial studies the following conditions: Tricuspid Regurgitation, Tricuspid Valve Disease.
What interventions are being tested in trial NCT06137807?
The interventions under investigation include: TricValve® Transcatheter Bicaval Valve System (DEVICE).
Who is sponsoring clinical trial NCT06137807?
This trial is sponsored by P+F Products + Features USA, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06137807 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tricuspid Regurgitation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06137807's enrollment target sits among peer trials
50 12th of 17 higher than 6 of 17 other Tricuspid Regurgitation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tricuspid Regurgitation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TTVR Early Feasibility Study
RECRUITING · NA
-
Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation ( VISTA-US)
RECRUITING · NA
-
Early Feasibility Study (EFS) Laplace Transcatheter Tricuspid Valve Replacement (TTVR) System
RECRUITING · NA
-
Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial
RECRUITING · NA
-
Trisol System EFS Study
RECRUITING · NA
-
EFS of the DUO System for Tricuspid Regurgitation
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI